Trial Profile

A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA 1011 (Primary) ; MRNA 1012 (Primary) ; MRNA-1010
Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza virus infections
Focus Adverse reactions
Sponsors Moderna Therapeutics

01 Jan 2025 Results (n=699; Between March 27 and May 9, 2023) assessing Safety and immunogenicity of mRNA-based seasonal influenza vaccines, published in The Lancet Infectious Diseases
20 Nov 2023 Status changed from active, no longer recruiting to completed.
17 May 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com